Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christof Seidl

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 24, 2017
Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in RadiotherapyAlexander Wurzer, Christof Seidl, Alfred Morgenstern, et al.
Plos One|June 1, 2013
Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenationChristian Wulbrand, Christof Seidl, Florian C Gaertner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 2, 2009
Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude miceBirgit Pfost, Christof Seidl, Michael Autenrieth, et al.
Cancer Science|June 15, 2007
213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude miceRoswitha Beck, Christof Seidl, Birgit Pfost, et al.
Plos One|February 28, 2019
Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patientsWeiwei Gong, Yueyang Liu, Christof Seidl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2012
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosisMarkus Essler, Florian C Gärtner, Frauke Neff, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2007
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imagingH Matthias Buchhorn, Christof Seidl, Roswitha Beck, et al.
Cancer Biology & Therapy|July 16, 2015
Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinomaJulia Fazel, Silvia Rötzer, Christof Seidl, et al.
BMC Cancer|July 17, 2019
Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancerWeiwei Gong, Yueyang Liu, Christof Seidl, et al.
Molecular Cancer Therapeutics|August 19, 2007
213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastropheChristof Seidl, Matthias Port, Klaus-Peter Gilbertz, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 24, 2017
Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in RadiotherapyAlexander Wurzer, Christof Seidl, Alfred Morgenstern, et al.
Plos One|June 1, 2013
Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenationChristian Wulbrand, Christof Seidl, Florian C Gaertner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 2, 2009
Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude miceBirgit Pfost, Christof Seidl, Michael Autenrieth, et al.
Cancer Science|June 15, 2007
213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude miceRoswitha Beck, Christof Seidl, Birgit Pfost, et al.
Plos One|February 28, 2019
Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patientsWeiwei Gong, Yueyang Liu, Christof Seidl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2012
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosisMarkus Essler, Florian C Gärtner, Frauke Neff, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2007
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imagingH Matthias Buchhorn, Christof Seidl, Roswitha Beck, et al.
Cancer Biology & Therapy|July 16, 2015
Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinomaJulia Fazel, Silvia Rötzer, Christof Seidl, et al.
BMC Cancer|July 17, 2019
Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancerWeiwei Gong, Yueyang Liu, Christof Seidl, et al.
Molecular Cancer Therapeutics|August 19, 2007
213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastropheChristof Seidl, Matthias Port, Klaus-Peter Gilbertz, et al.
Pageof 5